Immunosuppression of experimental systemic lupus erythematosus and antiphospholipid syndrome.
Shoenfeld
Y
Y
Department of Medicine, Tel-Aviv University, Israel.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000728:Androgens / Q000494:pharmacology; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology; D016736:Antiphospholipid Syndrome / Q000276:immunology / Q000628:therapy*; D001241:Aspirin / Q000494:pharmacology; D016026:Bone Marrow Transplantation; D001971:Bromocriptine / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D004195:Disease Models, Animal; D004967:Estrogens / Q000494:pharmacology; D005030:Ethylenes / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006912:Hydroxyquinolines / Q000494:pharmacology; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D017710:Lymphocyte Transfusion; D051379:Mice; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D000276:Adjuvants, Immunologic; D000728:Androgens; D000888:Antibodies, Anti-Idiotypic; D004967:Estrogens; D005030:Ethylenes; D006912:Hydroxyquinolines; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; C045282:roquinimex; D001971:Bromocriptine; C054105:ammonium trichloro(dioxoethylene-O,O'-)tellurate; D016572:Cyclosporine; D006493:Heparin; D001241:Aspirin